ClinicalTrials.gov
public full text
Public Domain
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints. The study will randomise 450 children to 3 groups: group A will receive measles containing vaccine (MCV) at 6 and 12 months ; group B at 9 and 18 months; Group C at 6 and 18 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vaccine Therapy in Treating Patients With Metastatic Melanoma#1174273
- Reconsidering Inducing Immunity? A Reply to Our Critics.#364525
- U.S. Measles Outbreaks 2025-2026: Overview and Issues for Congress#1137105
- A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)#865679
- Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.#353340
Record · ID 826556
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive